Capital Fund Management S.A. Takes Position in Syndax Pharmaceuticals, Inc. $SNDX

Capital Fund Management S.A. purchased a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 178,289 shares of the company’s stock, valued at approximately $1,670,000. Capital Fund Management S.A. owned approximately 0.21% of Syndax Pharmaceuticals at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Franklin Resources Inc. raised its holdings in Syndax Pharmaceuticals by 14.5% in the 2nd quarter. Franklin Resources Inc. now owns 2,359,677 shares of the company’s stock valued at $22,098,000 after acquiring an additional 298,272 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Syndax Pharmaceuticals by 1.3% in the second quarter. Geode Capital Management LLC now owns 2,049,350 shares of the company’s stock valued at $19,195,000 after purchasing an additional 26,365 shares during the last quarter. Algert Global LLC lifted its position in Syndax Pharmaceuticals by 12.6% during the first quarter. Algert Global LLC now owns 884,600 shares of the company’s stock worth $10,867,000 after buying an additional 98,968 shares in the last quarter. Candriam S.C.A. boosted its stake in Syndax Pharmaceuticals by 49.9% during the second quarter. Candriam S.C.A. now owns 675,085 shares of the company’s stock worth $6,322,000 after buying an additional 224,650 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in Syndax Pharmaceuticals by 1.6% during the first quarter. Adage Capital Partners GP L.L.C. now owns 631,640 shares of the company’s stock worth $7,760,000 after buying an additional 9,800 shares during the last quarter.

Insider Buying and Selling

In other news, CEO Michael A. Metzger sold 157,307 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $16.41, for a total transaction of $2,581,407.87. Following the completion of the transaction, the chief executive officer directly owned 298,661 shares in the company, valued at $4,901,027.01. This trade represents a 34.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.10% of the stock is owned by company insiders.

Syndax Pharmaceuticals Trading Up 0.2%

NASDAQ SNDX opened at $19.74 on Friday. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.58 and a 12 month high of $20.20. The stock has a market capitalization of $1.72 billion, a P/E ratio of -5.47 and a beta of 0.48. The firm’s 50-day moving average is $16.20 and its two-hundred day moving average is $13.49. The company has a debt-to-equity ratio of 2.78, a current ratio of 4.64 and a quick ratio of 4.42.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.04. The business had revenue of $45.87 million for the quarter, compared to the consensus estimate of $49.08 million. Syndax Pharmaceuticals had a negative net margin of 279.31% and a negative return on equity of 160.60%. The business’s revenue was up 266.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.98) EPS. On average, sell-side analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

SNDX has been the topic of several analyst reports. Stifel Nicolaus started coverage on Syndax Pharmaceuticals in a report on Wednesday, September 10th. They set a “buy” rating and a $44.00 price target on the stock. Guggenheim began coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, September 4th. They set a “buy” rating and a $34.00 price objective for the company. BTIG Research reiterated a “buy” rating and issued a $56.00 target price on shares of Syndax Pharmaceuticals in a report on Monday, October 27th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Syndax Pharmaceuticals in a research note on Monday, October 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.20.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).